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Cost-Effectiveness of a Heart Failure
Management Program From the
Societal Perspective?
I read with great interest the study by Capomolla et al. (1), which
was recently published in this Journal. The investigators assessed
the cost-effectiveness of an interdisciplinary heart failure manage-
ment program delivered by day-hospital compared with usual care.
In times of increasing pressures to contain health care resource
consumption, the study by Capomolla and colleagues represents an
important contribution to the literature.
The investigators state that their cost-effectiveness analysis was
conducted from the societal perspective, whereas it actually repre-
sents an analysis from the health care perspective. When defining
the perspective of an economic evaluation, the following key issues
need to be considered in order to be in line with a societal
viewpoint:
The type of costs in economic evaluation. In an analysis from
the societal perspective, all costs are included. In addition to health
care costs, productivity costs should have been assessed (2,3). This
is important if the age of the study population is relatively young.
The average age in the study by Capomolla et al. (1) was 56 years.
The researchers might have therefore missed a significant propor-
tion of the costs from a societal perspective, thereby probably
underestimating the cost-effectiveness of the interdisciplinary heart
failure management program, a program that might help to avert
future production losses in that it enables the sick person to work
again or work until later in his or her life.
Time horizon of the analysis. From an economic perspective,
the appropriate time horizon for a trial would include all of the
time when there is resource use related to heart failure (4). Because
heart failure is a chronic disease, a life-long treatment/
management is necessary. Accordingly, to agree with a societal
perspective, the follow-up period of 12  3 months of the
within-trial evaluation might have been expanded within a mod-
eling framework. In such a simulation study, one would describe
the course of the disease with and without the intervention for a
patient’s lifetime. The simulated societal costs and (untruncated)
life-expectancy resulting from the two strategies would then be
compared in an incremental analysis.
The utility of health states. The utility values were elicited
from patients using the time trade-off technique. In a societal
cost-effectiveness analysis, it is not the patients’ utilities but the
utilities that society attributes to the health states experienced by
the patient that should be included in the study. That is, a random
sample of the general public should have been asked to estimate
utilities from the societal perspective. Alternatively, the EuroQoL
questionnaire (5), a generic measure of quality of life, could have
been administered to the patients in the study. Value sets are
available that can be used to attach societal utility values to the
health states described by the patient in the EuroQoL question-
naire.
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REPLY
We thank Dr. Sendi for the methodological considerations of our
study.
The type of costs in economic evaluation. In our economic
analysis we considered both direct health costs and indirect costs
(as missing profit). The choice of evaluating the former costs was
a consequence of the management strategy. In the analysis of
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indirect costs, we measured the lost days of work. However, despite
their young age, all the subjects analyzed in our study were retired.
This can be explained by the fact that our center, being a pre-heart
transplantation facility, formally selects more compromised pa-
tients. However, the analysis of their functional characteristics
(LVEF, peak VO2) highlights that the ability to work was, in fact,
preserved in some subgroups of patients. We believe that this
“black hole” has been produced by a lack of published data that has
been translated into legislative misunderstanding. Our recent
experience about patients not entered into a program of evaluation
for cardiac transplantation pointed out that the frequency of return
to work was low and essentially completely detached from clinical
and functional characteristics (1). We could have used the method
of willingness to pay; this involved the introduction of another
subjective variable, but one that should have been randomly and
homogeneously distributed between the two groups and thus not
have biased the cost analysis.
Time horizon of the analysis. The building of the model
requires the survival curves of a representative population of the
considered sample to be extrapolated to zero. The introduction of
new therapies, such as beta-blockers and antialdosteronic agents,
has so drastically modified the course of the survival curves that by
the point at which the curves reached zero, the differences would
be extremely large (2,3). Hence, we applied our analysis to a
relatively short time window. Indeed, analysis of our database of
1,062 patients puts these different temporal courses of illness into
perspective (1991–1995: cardiac deaths: 198/495 (40%); 1996–
2002: cardiac deaths: 114/567 (20%). These methodological prob-
lems were reported in the study limitations.
The utility of health states. We agree with Dr. Sendi that in
a societal perspective the time trade-off (TTO) to quantify the
utility of the patient is that attributed by the society. The question
of how to quantify this remains substantially open (4). The
EuroQoL questionnaire does not eliminate the problem of sub-
jectivity in attributing the utility of illness. Different studies have
underlined that, substantially, the EuroQoL-visual analogue scale
(VAS) has been validated with a TTO method. Moreover, VAS
valuations can be affected by social class and education of patients
(5,6). Finally, in a recent report, TTO utility scores fitted with the
usual quality-of-life measures (7).
We warmly thank Dr. Sendi for his methodological clarifica-
tions as we firmly believe that only full interchange between those
proposing, implementing, and evaluating management strategies
in public health will lead to the combination of optimal health care
and optimal use of society’s resources (8).
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Use of Spironolactone in Heart Failure
Patients Receiving Angiotensin-Converting
Enzyme Inhibitors and Beta-Blockers
We read with great interest the report by Bozkurt et al. (1) which
raises important issues related to translation of research findings
into clinical practice. This is especially important for the use of
spironolactone for patients with heart failure and left ventricular
systolic dysfunction who are already receiving a beta-blocker. The
investigators demonstrated significant dissimilarities between pa-
tients enrolled in the Randomized Aldactone Evaluation Study
(RALES) and clinical practice, which might have resulted in
increased adverse effects. However, perhaps the single most im-
portant variable, the increasing dissimilarity of which will likely
determine the future role of spironolactone in heart failure pa-
tients, is use of beta-blockers. Only 11% of the RALES partici-
pants were receiving a beta-blocker (2). The American College of
Cardiology and American Heart Association heart failure guide-
lines recommend that all stable patients with heart failure and left
ventricular systolic dysfunction should receive a beta-blocker unless
specific contraindication exists (3). The weight of evidence for use
of a beta-blocker is stronger than that for spironolactone, and it is
expected that appropriate use of beta-blocker will increase in
the future. Data from the Valsartan Heart Failure Trial (Val-
HeFT) demonstrated that extensive blockade of multiple neu-
rohormonal systems in patients with heart failure may not be
desirable and may be associated with adverse outcomes (4). In
the Val-HeFT study, among patients receiving both an
angiotensin-converting enzyme (ACE) inhibitor and a beta-
blocker at baseline, use of valsartan was associated with over
40% increase in the risk of death (p  0.009) and nearly 20%
increase in the risk of combined end point of mortality and
morbidity (p  0.10). The impact of use of spironolactone on
heart failure patients already receiving an ACE inhibitor and a
beta-blocker is currently unknown. New randomized controlled
trials should be conducted before spironolactone could be
recommended for such patients.
The study also highlighted that hasty adoption of research
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